Fundraising Fox
Quoinpharma
Ashburn, US · Founded 2018 · 1 known investors
Find your way into Quoinpharma
Sign up to find every way you can get introduced to Quoinpharma
- Your email: who you already know at Quoinpharma, and who your contacts know
- 2nd- and 3rd-degree connections: people you know who worked, studied or invested with the Quoinpharma team
- Your LinkedIn: the connections who can make the intro for you
We rank every route by how warm it is, so you raise on warm intros instead of cold emails.
Quoin Pharmaceuticals is a pharmaceutical company developing therapeutic products for rare diseases, with a lead candidate, QRX003, in clinical trials for Netherton Syndrome. It plans commercial operations in the US, Western Europe, and Japan, supported by international marketing and distribution partnerships across 61 countries.
Founders & leadership
Quoinpharma was founded in 2018 by Michael Myers, Denise Carter, and MICHAEL MEYERS.
MM
Michael MyersCo-founder
MM
MICHAEL MEYERSCo-founder
SB
Sally Bridget LawlorExecutive
EL
Eyal LeibovitzExecutive
SY
Shai YarkoniExecutive
Board
KN
Kasbian Nuriel ChirichBoard director
NL
Natalie LeongBoard director
JC
Joseph CooperBoard director
JC
James CulverwellBoard director
MS
Michael SemberBoard director
DL
Dennis LangerBoard director
Investors · 1
Reported raises · per SEC filings
Form D private placements$166.5M disclosed across 7 rounds · 2017–2026
▶$50MraisedSep 2026 · 33 investors · PharmaceuticalsRule 506(b)
▶$50MraisedSep 2026 · 33 investors · Pharmaceuticals
Rule 506(b)Officers, directors & promoters on the filing
- Michael MyersExecutive Officer, Director
- Sally Bridget LawlorExecutive Officer
- Denise CarterExecutive Officer, Director
- Joseph CooperDirector
- James CulverwellDirector
- Dennis LangerDirector
- Natalie LeongDirector
- Michael SemberDirector
- Offering amount
- $50M
- Amount sold
- $50M
- Sales commissions
- $3M
- Placement agents
- Leerink Partners LLC, BTIG, LLC, Lake Street Capital Markets, LLC
- First sale
- Aug 2026
- Incorporated
- Corporation, Israel
- Federal exemptions
- 06b
▶$105.3MraisedOct 2025 · 27 investors · PharmaceuticalsRule 506(b)
▶$105.3MraisedOct 2025 · 27 investors · Pharmaceuticals
Rule 506(b)Officers, directors & promoters on the filing
- Natalie LeongDirector
- Michael MyersExecutive Officer, Director
- Sally Bridget LawlorExecutive Officer
- Denise CarterExecutive Officer, Director
- Joseph CooperDirector
- James CulverwellDirector
- Michael SemberDirector
- Dennis LangerDirector
- Offering amount
- $105.3M
- Amount sold
- $105.3M
- Sales commissions
- $1.2M
- Placement agents
- Maxim Group LLC
- First sale
- Oct 2025
- Incorporated
- Corporation, Israel
- Federal exemptions
- 06b
▶$193.5KraisedAug 2022 · 1 investors · PharmaceuticalsRule 506(b)
▶$193.5KraisedAug 2022 · 1 investors · Pharmaceuticals
Rule 506(b)Officers, directors & promoters on the filing
- James CulverwellDirector
- Gordon DunnExecutive Officer
- Michael SemberDirector
- Denise CarterExecutive Officer, Director
- Natalie LeongDirector
- Michael MyersExecutive Officer, Director
- Joseph CooperDirector
- Dennis LangerDirector
- Offering amount
- $193.5K
- Amount sold
- $193.5K
- First sale
- Aug 2022
- Incorporated
- Corporation, Israel
- Federal exemptions
- 06b
▶$2MraisedApr 2021 · 1 investors · PharmaceuticalsRule 506(b)
▶$2MraisedApr 2021 · 1 investors · Pharmaceuticals
Rule 506(b)Officers, directors & promoters on the filing
- PETER LANKAUDirector
- NATALIE LEONGDirector
- DENISE CARTERExecutive Officer, Director
- MICHAEL MEYERSExecutive Officer, Director
- DENNIS LANGERDirector
- Offering amount
- $22M
- Amount sold
- $2M
- Sales commissions
- $945K
- Placement agents
- JMP SECURITIES LLC
- First sale
- Mar 2021
- Incorporated
- Corporation, Delaware, 2018
- Federal exemptions
- 06b
▶$710KraisedOct 2020 · 3 investors · PharmaceuticalsRule 506(b)
▶$710KraisedOct 2020 · 3 investors · Pharmaceuticals
Rule 506(b)Officers, directors & promoters on the filing
- MICHAEL MEYERSExecutive Officer, Director
- PETER LANKAUDirector
- DENNIS H. LANGERDirector
- DENISE CARTERExecutive Officer, Director
- Offering amount
- $3M
- Amount sold
- $710K
- Minimum investment
- $100K
- First sale
- Oct 2020
- Incorporated
- Corporation, Delaware, 2018
- Federal exemptions
- 06b
▶$4MraisedFeb 2018 · 3 investors · PharmaceuticalsRule 506(b)
▶$4MraisedFeb 2018 · 3 investors · Pharmaceuticals
Rule 506(b)Officers, directors & promoters on the filing
- Yuval BermanDirector
- Eyal LeibovitzExecutive Officer
- David BraunDirector
- Michael BerelowitzDirector
- Abraham NahmiasDirector
- Shai YarkoniExecutive Officer, Director
- Ruth Ben YakarDirector
- Kasbian Nuriel ChirichDirector
- Ruhama AvrahamDirector
- Offering amount
- $4M
- Amount sold
- $4M
- Sales commissions
- $280K
- Placement agents
- H.C. Wainwright & Co., LLC
- First sale
- Jan 2018
- Incorporated
- Corporation, Israel
- Federal exemptions
- 06b
▶$4.3MraisedSep 2017 · 18 investors · PharmaceuticalsRule 506(b)
▶$4.3MraisedSep 2017 · 18 investors · Pharmaceuticals
Rule 506(b)Officers, directors & promoters on the filing
- Abraham NahmiasDirector
- Yuval BermanDirector
- Eyal LeibovitzExecutive Officer
- Michael BerelowitzDirector
- David GrossmanDirector
- Shai YarkoniExecutive Officer, Director
- Ruth Ben YakarDirector
- Kasbian Nuriel ChirichDirector
- Offering amount
- $4.3M
- Amount sold
- $4.3M
- Sales commissions
- $85K
- Placement agents
- H.C. Wainwright & Co., LLC
- First sale
- Sep 2017
- Incorporated
- Corporation, Israel
- Federal exemptions
- 06b
Source: SEC EDGAR Form D. Amounts as filed; amended filings shown once at their latest values.
Related companies · 7
StockTwitsStocktwits operates an online community platform where investors and traders share ideas, analysis, and trade discussions organized around stock tickers. The page presented is its community guidelines rather than a product description.
RobinhoodRobinhood is a financial trading platform that enables users to manage portfolios across stocks, ETFs, cryptocurrencies, options, futures, and prediction markets. The platform serves retail investors with low barriers to entry, offering portfolio management services and market insights.
PerplexityAn AI-powered answer engine providing accurate, trusted, and real-time answers to questions.
TradingViewTradingView is a charting platform and social network used by over 100 million traders and investors worldwide to analyze and trade across global financial markets. The platform provides tools for technical analysis, market data, and community collaboration for retail and institutional traders.
NasdaqNasdaq operates a technology infrastructure platform for financial markets across three business segments: Capital Access Platforms (which includes listing services, indices, and analytics tools), Financial Technology (comprising compliance, regulatory, and capital markets software), and Market Services (equities and derivatives trading operations). The company serves financial institutions, listed companies, investment managers, and regulatory agencies globally.
TipRanksFinancial analysis and stock research platform.
PublicPublic is a trading platform that allows users to buy and sell cryptocurrencies including Bitcoin, Ethereum, and memecoins through accounts managed by Zero Hash LLC, a New York State-licensed virtual currency business.
Companies working in the same space as Quoinpharma.
Frequently asked questions
- What does Quoinpharma do?
- Quoin Pharmaceuticals is a pharmaceutical company developing therapeutic products for rare diseases, with a lead candidate, QRX003, in clinical trials for Netherton Syndrome. It plans commercial operations in the US, Western Europe, and Japan, supported by international marketing and distribution partnerships across 61 countries.
- Who founded Quoinpharma?
- Quoinpharma was founded by Michael Myers, Denise Carter, MICHAEL MEYERS in 2018.
- Who are Quoinpharma's investors?
- Quoinpharma's investors include Altium Capital.
- How much funding has Quoinpharma raised?
- Quoinpharma has disclosed $166.5M raised across 7 rounds.
- Where is Quoinpharma headquartered?
- Quoinpharma is headquartered in Ashburn, US.